摘要
目的:评价中化联合治疗老年中晚期非小细胞肺癌(NSCLC)的临床获益及安全性。方法:计算机检索Cochrane library、Medline、Embase、Springer link、NCKI、VIP、万方数据库,检索时限:1996-01/2011-11。检索文种不限制。收集所有中药联合化疗治疗老年中晚期NSCLC的随机对照试验(RCT),筛选出符合纳入标准的文献,经质量评价后,采用Cochrane协作网提供的RevMan5.1.0软件对纳入研究结果进行Meta分析。结果:共检索到相关文献140篇,最终纳入18个RCT。Meta分析结果显示:中化联合方案在生存期、生活质量、客观临床疗效及某些毒副反应方面均较单纯的化疗方案效果更好。结论:中化联合方案更适用于老年中晚期NSCLC患者,值得临床上大力推广。
Objective：To compare and assess the effectiveness and safety of Traditional Chinese Medicine in combination with chemotherapy versus chemotherapy for senile mid-advanced non-small cell lung cancer.Methods：To collect all of RCTs with Traditional Chinese Medicine in combination with chemotherapy versus chemotherapy for senile mid-advanced non-small cell lung cancer from the Cochrane library,Medline,Embase,Springer link,CNKI,VIP and Wanfang in the internet.The published time of all studies was from Jan.1996 to Nov.2011.The language included English and Chinese.Finally the data of chosen studies was analyzed according to the Cochrane Handbook for Systematic Reviews.Result：Eighteen studies involving 1108 patients were included,with 578 patients in the experimental group of Traditional Chinese Medicine in combination with chemotherapy and the rest in the control group of chemotherapy.The experimental group was superior to the control group in prolonging overall survival,enhancing the quality of life and clinical effectiveness,being lower adverseness in thrombopenia,anemia,digestive reaction and hepatic injury.But the two groups had no significance of difference in leucopenia and renal injury.Conclusion：The regimen of traditional Chinese medicine in combination with chemotherapy is more appropriate for the treatment of senile mid-advanced non-small cell lung cancer.
出处
《辽宁中医药大学学报》
CAS
2012年第12期54-57,共4页
Journal of Liaoning University of Traditional Chinese Medicine
基金
广西中医药管理局计划课题(Gzkz09-37)
关键词
中药
化疗
中晚期
非小细胞肺癌(NSCLC)
系统评价
traditional Chinese medicine
chemotherapy
mid-advanced
non-small cell lung cancer
systematic review
